Kedrion Biopharma Recognized for innovation in Treating Rare Disease
Jun 28, 2022 |
CORPORATE
Prestigious recognition presented for the first ever treatment for Plasminogen Deficiency
World Hemophilia Day: Kedrion’s commitment
Apr 13, 2022 |
CORPORATE
Guaranteeing equitable access to treatment is the central theme of the 2022 edition
Kedrion-Pharmacosmos partnership for the treatment of Anemia in Italy
Mar 03, 2022 |
CORPORATE
Exclusive agreement signed for the distribution of a novel iron-based therapy
Val Romberg completes his assignement as Kedrion’s CEO
Jan 31, 2022 |
CORPORATE
Kedrion and LFB sign industrial cooperation agreement
Jan 31, 2022 |
CORPORATE
Scope is supplying Immunoglobulins to meet patient demand in France
Kedrion grows in North America as it completes acquisition of Prometic
Oct 18, 2021 |
CORPORATE
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Kedrion Biopharma expands its commitment in Turkey
Oct 14, 2021 |
CORPORATE
Expansion plans revealed at Embassy reception in Ankara on October 14
4ID – Kedrion proud to support new App for patients with Immunodeficiencies
Oct 04, 2021 |
CORPORATE
Our company restates its long-standing and consistent collaboration with IPOPI
KIDCARES10, First Patient Treated in Pediatric PI Study
Jul 26, 2021 |
CORPORATE
Thirty patients aged 2 to 17yo to be enrolled over five European countries